polatuzumab vedotin,Glofitamab,Obinutuzumab,Tocilizumab
roche,JW Pharma
['pola', 'dlbcl', 'lymsm']
summary slide for glofi + pola in r/r dlbcl. cr 44% in hgbl and previous car exposure. crs mostly low grade. #17icml #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈